Metformin for advanced colorectal cancer with chemotherapy
Part of Cancer clinical trials.
This trial tests whether adding metformin (a diabetes drug) to standard chemotherapy (FOLFIRI) and targeted therapy can help people with metastatic colorectal cancer live longer or respond better to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 90 years old.
- You have metastatic colorectal cancer and your doctor plans FOLFIRI chemotherapy for you.
- If female, you are not pregnant, not breastfeeding, and willing to use birth control during the study.
- You do not have serious heart, kidney, liver, or other major disease problems controlled by your doctor.
- You are not allergic to metformin or any study drugs.
- You are able to take medicines as instructed and sign a consent form.
- Your blood sugar level is above 80 mg/dL.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding metformin, a common diabetes drug, to standard chemotherapy or immunotherapy can help treat advanced solid tumors. It may be an option for people who are already eligible for chemo or immunotherapy.
This trial tests a combination of two medications, fruquintinib (a targeted drug that stops blood vessel growth) and a chemotherapy pill called tegafur/gimeracil/oteracil (often used after standard chemo has stopped helping). The goal is to see if this combination can help control advanced colorectal cancer that has not responded to at least two prior treatments.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This study tests if metformin, a common diabetes medicine, can help reduce insulin resistance in women who finished chemotherapy for early-stage breast cancer. It aims to improve long-term health and prevent future problems.
This Phase 3 study tests whether adding metformin to standard targeted medicines (tyrosine kinase inhibitors) helps people with EGFR-mutated non-small cell lung cancer. It’s meant for people who haven’t already had EGFR-targeted treatment and who have healthy enough labs and organs to safely take the study medicines.
This trial tests a combination of two oral medications for people with advanced colorectal cancer who cannot tolerate stronger chemotherapy. The goal is to see if this gentler approach slows tumor growth and improves quality of life.
Hear when a new Progression-Free Survival trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.